Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 5% · narrower than the standard 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Bal Pharma Ltd is engaged in the manufacturing of API, finished formulations, ayurvedic and research and development. They are one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives. The company offers products for treatment of diabetes, cardiometabolics, gynaecology, dermatology, gastroenterology, orthopaedics, ENT and multi-speciality segments.They also produce a range of APIs that includes Anti Histamine, Platelet inhibitor, Antidiabetic, Anti Convulsant, urinary incontinence, Neuropathic pain, Anti allergy, Anti inflammatory, Diuretic, Acne Treatment etc.Their R&D unit is also engaged in developing processes for novel bulk actives (active pharmaceutical ingredients, APIs) and new chemical substances for therapeutic applications.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Bengaluru (Bangalore), Karnataka
- CEO & MD
- Shailesh D Siroya
- Registrar
- TSR Darashaw Consultants Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE083D01012
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Bal Pharma Ltd today?
Bal Pharma Ltd (BALPHARMA) is trading at ₹81.09. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is BALPHARMA’s P/E ratio versus the sector?
BALPHARMA trades at a P/E of 19.5. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is BALPHARMA’s dividend yield?
BALPHARMA has a dividend yield of 1.29%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is BALPHARMA’s 52-week high and low?
BALPHARMA has traded between ₹60 and ₹124.6 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Bal Pharma Ltd?
Bal Pharma Ltd has a market capitalisation of ₹148 crore.
▶What is BALPHARMA’s return on equity?
BALPHARMA reports a return on equity of 6.6%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are BALPHARMA’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is BALPHARMA’s promoter holding?
Promoters hold 50.87% of BALPHARMA. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include BALPHARMA?
Index membership is listed in the Context block on this page, along with the weight BALPHARMA carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Bal Pharma Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from BALPHARMA’s own numbers. The judgement is yours.
BALPHARMA at a glance
Bal Pharma Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Bal Pharma Ltd (BALPHARMA) last traded at ₹81.09, giving it a market capitalisation of ₹148 crore. The 52-week range is ₹60 to ₹124.6, and the price is 33% of the way up that range. It trades at a price-to-earnings ratio of 19.5. Promoters hold 50.87% of the company in the latest shareholding filing.
| Market cap | ₹148 crore |
|---|---|
| P/E | 19.5 |
| ROE | 6.6% |
| ROCE | 9.3% |